Alnylam Pharmaceuticals

The Company is engaged in the research and development of therapeutics based on its ribonucleic acid interference (RNAi). The Company’s pipeline focuses in three strategic therapeutic areas (STArs): Genetic Medicines, with a pipeline of RNAi therapeutics for the treatment of rare diseases; Cardio-Metabolic Disease, with a pipeline of RNAi therapeutics toward genetically validated, liver-expressed disease in cardiovascular and metabolic diseases, and hepatic infectious disease, with a pipeline of RNAi therapeutics for treatment of hepatic infectious diseases. Its products include Patisiran (ALN-TTR02), Revusiran (ALN-TTRsc), ALN-AT3, ALN-CC5, ALN-AS1, ALN-AAT, ALN-GO1, ALN-TMP, ALN-PCS, ALN-PCSsc, ALN-AC3, ALN-ANG, ANGPTL3, ALN-HBV, ALN-HDV and ALN-PDL. The Company is developing two investigational RNAi therapeutic candidates for TTR-Mediated Amyloidosis (ATTR): patisiran and revusiran.
Type
Public
HQ
Cambridge, US
Founded
2002
Employees
369 (est)+31%
Alnylam Pharmaceuticals was founded in 2002 and is headquartered in Cambridge, US

Key People at Alnylam Pharmaceuticals

Saraswathy (Sara) Nochur

Saraswathy (Sara) Nochur

Senior Vice President, Regulatory Affairs & Quality Assurance
Muthiah (Mano) Manoharan

Muthiah (Mano) Manoharan

Senior Vice President, Drug Discovery
Lubomir (Lubo) Nechev

Lubomir (Lubo) Nechev

Vice President, Process Sciences
Mary Beth DeLena

Mary Beth DeLena

VP, Legal
David Bartel

David Bartel

Scientific Advisory Board and Founder
Oved Amitay

Oved Amitay

Vice President, Head of Commercial

Alnylam Pharmaceuticals Locations

Cambridge, US
Uxbridge, GB
Cambridge, US

Alnylam Pharmaceuticals Metrics

Alnylam Pharmaceuticals Summary

Market capitalization

$3.5 B

Closing share price

$40.3
Alnylam Pharmaceuticals's latest market capitalization is $3.5 B.

Alnylam Pharmaceuticals Market Value History

Alnylam Pharmaceuticals News

Alnylam Pharmaceuticals Company Life

You may also be interested in